None
 Buy), and his $30 price target implies a 43% upside potential for the next 12 months.
(To watch Anmuth’s track record, click here)Wall Street is quite positive on this 'Moderate Buy' stock: WISH has received 8 'buy' and 4 'hold' ratings in the last three months.
Running the numbers across the Street, the 12-month average price target lands at $26, representing about 24% upside potential.
(See WISH stock analysis on TipRanks)Passage Bio (PASG)The second JPM pick we’re looking at is Passage Bio, a genetic medicines company.
Shares sell for $26.25, and the average price target of $32.83 indicates an upside of ~25%.